Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Monopar Therapeutics (NASDAQ:MNPR) from a sell rating to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.

A number of other brokerages have also issued reports on MNPR. Cantor Fitzgerald lowered shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the company from $109.00 to $119.00 in a report on Thursday, August 13th. Zacks Research downgraded shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. BTIG Research upped their target price on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a research note on Thursday, July 23rd. Finally, HC Wainwright raised their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $120.08.

Monopar Therapeutics Stock Down 1.8%

NASDAQ:MNPR opened at $108.32 on Friday. The business’s 50-day simple moving average is $111.74 and its two-hundred day simple moving average is $79.59. The stock has a market cap of $727.04 million, a PE ratio of -49.92 and a beta of 1.49. Monopar Therapeutics has a 52 week low of $46.89 and a 52 week high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. Sell-side analysts anticipate that Monopar Therapeutics will post -2.94 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Kim Tsuchimoto sold 4,090 shares of the firm’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total value of $455,585.10. Following the completion of the transaction, the director directly owned 7,396 shares of the company’s stock, valued at approximately $823,840.44. This trade represents a 35.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total transaction of $351,181.34. Following the sale, the director directly owned 23,751 shares in the company, valued at approximately $2,654,649.27. The trade was a 11.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.70% of the company’s stock.

Institutional Trading of Monopar Therapeutics

A number of large investors have recently made changes to their positions in the business. Sei Investments Co. lifted its holdings in shares of Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after acquiring an additional 656 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Monopar Therapeutics during the fourth quarter worth approximately $86,000. Your Advocates Ltd. LLP bought a new stake in Monopar Therapeutics during the first quarter worth approximately $183,000. The Manufacturers Life Insurance Company purchased a new stake in Monopar Therapeutics during the first quarter valued at approximately $250,000. Finally, California State Teachers Retirement System lifted its stake in shares of Monopar Therapeutics by 2,224.3% in the 2nd quarter. California State Teachers Retirement System now owns 5,741 shares of the company’s stock valued at $532,000 after purchasing an additional 5,494 shares during the last quarter. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company’s programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.

Monopar’s lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.